Premium
Regulation of Schwann cell nerve growth factor receptor by cyclic adenosine 3′,5′‐monophosphate
Author(s) -
Mokuno K.,
Sobue G.,
Reddy U. R.,
Wurzer J.,
Kreider B.,
Hotta H.,
Baron P.,
Ross A. H.,
Pleasure D.
Publication year - 1988
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.490210237
Subject(s) - adenosine , cyclic adenosine monophosphate , schwann cell , nerve growth factor , microbiology and biotechnology , neuroscience , adenosine monophosphate , receptor , chemistry , endocrinology , medicine , biology , biochemistry
Previous studies indicated that Schwann cells in immature nerves express nerve growth factor (NGF) receptors, and that this expression is down regulated during development but re‐induced by Wallerian degeneration. It was also shown that immature Schwann cells are induced to express galactocerebroside and other molecules characteristic of mature Schwann cells by either contact with an axon or treatment with the cyclic adenosine 3′,5′‐monophosphate (cAMP) analogues dibutyryl cAMP (dbcAMP) and 8‐bromo cAMP or the adenylate cyclase activator forskolin. In the present study, NGF receptors on the surface of cultured Schwann cells were demonstrated by binding of an anti‐rat NGF receptor monoclonal antibody or of radioiodinated NGF. Treatment of cultured Schwann cells with cAMP analogues or forskolin resulted in a progressive decrease in both immunoreactive NGF receptors and radioiodinated NGF binding. The cultured Schwann cells contained a polyadenylated RNA species homologous with human melanoma NGF receptor mRNA in sequence and size. The amount of this NGF mRNA was lower in cAMP analogue‐treated than in untreated Schwann cells.